CRIS Current Research Information System

AMABILE, MARILINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.981
EU - Europa 1.688
AS - Asia 596
AF - Africa 123
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.393
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.976
GB - Regno Unito 489
SE - Svezia 348
VN - Vietnam 249
DE - Germania 216
CN - Cina 202
IT - Italia 193
UA - Ucraina 102
IN - India 83
IE - Irlanda 74
FR - Francia 66
RU - Federazione Russa 56
TG - Togo 56
BE - Belgio 43
EE - Estonia 32
JO - Giordania 30
ZA - Sudafrica 30
CH - Svizzera 29
CI - Costa d'Avorio 24
GR - Grecia 16
FI - Finlandia 14
IR - Iran 11
TR - Turchia 8
SC - Seychelles 7
NG - Nigeria 6
NL - Olanda 6
CA - Canada 5
JP - Giappone 3
BR - Brasile 2
CL - Cile 2
IL - Israele 2
KR - Corea 2
LB - Libano 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
HK - Hong Kong 1
NO - Norvegia 1
PH - Filippine 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
Totale 4.393
Salva come PNG Salva come JPEG
Città #
Southend 443
Chandler 295
Fairfield 269
Woodbridge 141
Dong Ket 138
Houston 134
Wilmington 129
Seattle 126
Ann Arbor 107
Ashburn 98
Cambridge 90
Princeton 84
Dublin 74
Jacksonville 71
Lomé 56
Brussels 42
Nanjing 41
Westminster 40
Padova 37
Turin 34
Amman 30
Beijing 28
Berlin 25
Bern 25
Abidjan 24
Jinan 21
Saint Petersburg 21
Bologna 18
Bremen 16
Shenyang 16
Helsinki 14
San Diego 14
Boardman 13
Falls Church 12
Hebei 12
Medford 11
Washington 11
Nanchang 10
Taizhou 10
Dearborn 9
Des Moines 9
Florence 9
Haikou 9
Milan 9
Changsha 8
Jiaxing 8
Tianjin 8
Istanbul 7
Mahé 7
Mülheim 7
Abeokuta 6
Redmond 6
Zhengzhou 6
Hangzhou 5
Leawood 5
Norwalk 5
Groningen 4
Los Angeles 4
Mountain View 4
Olalla 4
Redwood City 4
Rome 4
Verona 4
Ferrara 3
Grafing 3
Guangzhou 3
Kashan 3
Kuban 3
Ningbo 3
Tokyo 3
Toronto 3
Andover 2
Athens 2
Bengaluru 2
Boston 2
Frankfurt Am Main 2
Frankfurt am Main 2
Fuzhou 2
Kish 2
Kunming 2
La Spezia 2
Lanzhou 2
Mumbai 2
North York 2
Orange 2
Riolo Terme 2
San Venanzo 2
Tappahannock 2
Tel Aviv 2
Zanjan 2
Amsterdam 1
Ardabil 1
Atlanta 1
Benevento 1
Castelnuovo Rangone 1
Castenaso 1
Cesenatico 1
Chengdu 1
Chicago 1
Cislago 1
Totale 3.003
Salva come PNG Salva come JPEG
Nome #
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 208
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 208
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 202
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 158
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 154
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 154
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 150
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 143
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 138
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 137
Patient-reported outcome measures (PROMs) after elective hip, knee and shoulder arthroplasty: Protocol for a prospective cohort study 135
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. 125
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 124
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 122
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 122
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. 118
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 118
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 115
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 112
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 110
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 108
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 101
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 101
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 99
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 96
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 95
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 88
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 87
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients 83
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 80
null 79
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 79
null 77
Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP 72
New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib 69
Patient-reported outcomes in patients undergoing elective arthroplasty: the PaRIS-IOR study 66
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 64
null 57
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. 54
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 42
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome 29
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 25
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. 20
Totale 4.524
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.774
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.774
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019264 0 0 2 45 10 39 18 9 28 47 22 44
2019/20201.231 157 25 13 91 164 134 149 149 145 76 47 81
2020/2021723 125 45 12 26 35 30 4 50 65 37 47 247
2021/2022924 102 13 56 106 79 68 18 52 35 83 160 152
2022/20231.130 125 217 55 140 56 91 40 49 189 25 97 46
2023/202486 12 50 24 0 0 0 0 0 0 0 0 0
Totale 4.524